Adagio Therapeutics (NASDAQ:ADGI – Get Rating) and Curis (NASDAQ:CRIS – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation and dividends. Institutional & Insider Ownership 88.7% of Adagio Therapeutics shares are […]
Exelixis (NASDAQ:EXEL – Get Rating) and Qiagen (NYSE:QGEN – Get Rating) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings. Valuation & Earnings This table compares Exelixis and Qiagen’s top-line revenue, earnings […]
– XL114 is a CARD11-BCL10-MALT1 pathway inhibitor with demonstrated activity in lymphoma models that are resistant to Bruton's tyrosine kinase inhibitors –ALAMEDA, Calif. (BUSINESS WIRE) Exelixis, Inc. (Nasdaq: EXEL) today announced initiation of the dose-escalation stage of the first-in-human phase 1 trial of XL1.